Market Pulse · Daily Scan
Daily Market Pulse
Jul 9, 2026 · sentiment/flow window ≈ 48h
Pre-marketnot publishedPost-market
TLDR;
US equities sit at/near record highs but hit a geopolitical air-pocket midweek. Wed Jul 8 pulled back (Dow -1.1%, S&P -0.3%) after President Trump declared the Iran ceasefire 'over', spiking oil ~5%; Thu Jul 9 rebounded (S&P +0.8%, Nasdaq +1.3%) on a semiconductor/AI rally and easing oil. Fed is on hold with sticky inflation and nonzero hike risk, so the regime is best described as 'risk-on but fragile / headline-driven near record highs.' Breadth: Positive but not robust. Advancers led decliners (~53% vs ~44% early July) and most MA-breadth readings are above 50%, but only ~52% of stocks are above their 200-day MA. Tech/chip leadership is doing the heavy lifting. (Breadth counts UNVERIFIED / tier-3.).A · Daily Pulse
What moved — and why
▲ Rising — dailycomposite
| # | Ticker | Move | Driver | Score |
|---|---|---|---|---|
| 1 | BABA | — | US ADR +~9% (HK shares +12.5%, biggest single-day gain since Sept) on a pre-earnings analyst briefing pointing to narrowing instant-commerce losses and cloud revenue growth accelerating toward ~45%; a ~$600M US DOJ non-prosecution settlement removed a legal overhang; broad China-tech rotation. Market cap approximate/UNVERIFIED. | 84 |
| 2 | ANET | — | +8.76% to ~$181.05 on a wave of Street PT hikes to ~$200 (KeyBanc $178->$200, BofA $185->$200, Morgan Stanley ->$190) citing 'exceptional' AI switch demand; new 1.6T 7060XE7 platform validated with Meta/Microsoft/Oracle. Market cap approximate/UNVERIFIED. | 82 |
| 3 | MU | — | +~7% on a plan to invest up to $3B to strengthen the US semiconductor supply chain, plus sharply higher DRAM contract pricing (Bernstein cited ~+74% QoQ conventional DRAM). Memory/HBM supercycle tailwind; cyclical-reversal risk. Market cap approximate/UNVERIFIED. | 80 |
| 4 | AVGO | — | +4.83% to ~$388.69 after Apple confirmed a multi-year chip deal reported >$30B (custom ASIC + RF through 2031), incl. a $1.5B Apple-backed expansion of Broadcom's Fort Collins, CO facility. Market cap approximate/UNVERIFIED. | 79 |
| 5 | MPC | — | +5.4% as crude/refined-product prices spiked on the Iran conflict; ULSD futures +13% after Russia banned diesel exports. Refiner group (PBF, DINO, VLO) outperformed. Move is macro/oil-driven and may reverse with oil. Market cap approximate/UNVERIFIED. | 74 |
| 6 | NVDA | — | +3.7% after The Information reported China may allow Alibaba/ByteDance/DeepSeek to buy a limited quantity of NVDA H200 chips. Mega-cap; exact market cap UNVERIFIED (aggregator figures did not reconcile to price). | 72 |
| 7 | BIDU | — | +~4.8% premarket in the broad China internet/e-commerce rally alongside Alibaba; sympathy/rotation move rather than a company-specific catalyst. Market cap approximate/UNVERIFIED. | 68 |
| 8 | MRVL | — | Gainer Jul 9 on sector-wide demand for communications/optical chips; SK Hynix's US ADR offering reportedly >7x oversubscribed lifted the memory/optical complex. Exact % UNVERIFIED. Market cap approximate/UNVERIFIED. | 66 |
| 9 | GLW | — | Named among optical-communications winners on AI datacenter demand (with COHR, LITE). Exact % UNVERIFIED. Market cap approximate/UNVERIFIED. | 63 |
| 10 | COP | — | +2.1% on the oil-price surge from Middle East escalation; macro/commodity-driven and sensitive to any oil reversal. Market cap approximate/UNVERIFIED. | 61 |
▼ Falling — dailycomposite
| # | Ticker | Move | Driver | Score |
|---|---|---|---|---|
| 1 | AZN | — | London shares -9% to -9.9% (~£19-27B erased) after the Phase III CARDIO-TTRansform trial of Wainua (with Ionis) missed its primary cardiovascular-mortality endpoint — a rare late-stage failure. US ADR early Jul 9 print (-1.99%) lagged the London selloff; London move is the accurate catalyst reaction. Market cap approximate/UNVERIFIED. | -78 |
| 2 | ORCL | — | Dropped below ~$140, down ~50% from June highs of ~$250.25, lower in 20 of the last 25 sessions — a sustained de-rating/momentum unwind with no single fresh catalyst. Mega-cap; exact market cap UNVERIFIED. Note: this is a multi-week move, not purely 48h. | -70 |
| 3 | CCL | — | -3.9% as the oil spike and Middle East escalation hit fuel-sensitive cruise names (RCL, NCLH also weak). Macro/oil-driven; could reverse with oil. Market cap approximate/UNVERIFIED. | -66 |
| 4 | PEP | — | -1.70% to ~$142.51 on weak US beverage scanner data (Bernstein cited volumes down ~6% trailing) and staples weakness, into Jul 9 pre-market Q2 earnings (consensus EPS ~$2.19-2.21). Specific catalyst partly UNVERIFIED. Market cap approximate/UNVERIFIED. | -67 |
| 5 | RCL | — | Weak with CCL on the same oil/geopolitical hit. Exact % UNVERIFIED. Market cap approximate/UNVERIFIED. | -58 |
| 6 | NCLH | — | Weak with the cruise group on oil/geopolitical risk-off. Exact % UNVERIFIED. Market cap approximate/UNVERIFIED (near threshold). | -55 |
| 7 | AA | — | Lower after Morgan Stanley cut to Equal Weight, PT to $53 from $79, citing new aluminum supply and Middle East smelter restarts pressuring prices (also cut VALE). Exact % UNVERIFIED. Market cap borderline ~$10-13B/UNVERIFIED. | -54 |
| 8 | BE | — | Tumbled midday Jul 8 on a Hunterbrook Media short report questioning Bloom's 'no China supply chain'/scandium-independence claims. Exact % UNVERIFIED; market cap borderline ~$10-15B/UNVERIFIED. PUMP_RISK flag raised (activist-short catalyst, high-volatility name, unverified figures) — caveat, not suppress. pump risk | -59 |
B · One-Year Conviction
Asymmetric 12-month skew
▲ Upside skew — 1yrconviction
| Ticker | Thesis | Key risk | Score |
|---|---|---|---|
| NVDA | Standard for AI accelerated computing (GPU + CUDA + networking), capturing the majority of a still-ramping hyperscaler AI-capex supercycle into 2027. Strong Buy consensus across ~60 analysts. | Extreme size caps further multiple expansion; hyperscaler customer concentration; AI-capex air-pocket risk; China export controls; custom-ASIC competition | 88 |
| AVGO | Custom AI ASIC (XPU) design wins across multiple hyperscalers plus AI networking silicon give a differentiated, high-margin second leg to the AI buildout beyond merchant GPUs; VMware adds recurring software revenue. | Lumpy custom-silicon order timing; customer concentration; rich valuation; VMware leverage/integration | 85 |
| MSFT | Azure AI + Copilot monetization across a Fortune-500 installed base; AI annualized revenue reported ~$37B (+123% YoY per aggregator). Demand-backed ~$190B FY26 capex signals confidence. | Heavy AI capex pressuring near-term FCF/margins (incl. ~$25B memory-price impact); Azure growth-deceleration concerns | 83 |
| GOOGL | Gemini integration across Search/Cloud plus Google Cloud acceleration and capacity expansion drive a multi-year AI/cloud monetization ramp. | AI-chat disruption of core Search; antitrust remedies; heavy capex pressuring FCF | 82 |
| META | AI-driven ad targeting/ranking plus re-accelerating engagement across the Family of Apps drives durable double-digit ad growth; Llama/AI-agents optionality. | Heavy AI/capex spend on margins; Reality Labs losses; regulatory/antitrust; ad-cycle sensitivity | 80 |
| AMZN | AWS re-acceleration (~28% YoY) on AI demand plus high-margin advertising scaling and retail margin expansion. | AWS capex intensity; consumer/retail softness; cloud competition from Azure/Google | 79 |
| LLY | Dominant GLP-1 franchise (Mounjaro + Zepbound ~$13B combined Q1 2026 revenue) in a category BofA sees roughly doubling US sales by 2033; oral GLP-1 (orforglipron) optionality. | GLP-1 competition (Novo, new entrants); pricing/reimbursement pressure; manufacturing capacity; trial/regulatory setbacks | 81 |
| GEV | Power-equipment leader (gas turbines, grid, nuclear/SMR) levered to data-center electricity demand; orders +71% YoY, backlog +$13B to $163B, FY26 revenue guide raised to ~$44.5-45.5B. | Wind-segment losses; long-cycle project execution/margins; supply-chain costs; valuation after a large run | 80 |
| VST | Data-center power demand + ERCOT tightness; nuclear/gas fleet with 20-year PPAs to Meta and AWS (~3,800 MW), ~5,500 MW Cogentrix gas acquisition, and Perry nuclear restart — scarcity value on 24/7 power. 2026 revenue forecast raised $18.8B->$23.3B; EPS $9.01->$9.40. | Merchant power-price volatility; execution on acquisitions/restarts; commodity/weather; regulatory | 78 |
| ETN | Electrical/power-management leader riding the AI data-center buildout — data-center orders +~240%, backlog ~228GW; Boyd Thermal / Ultra PCS deals deepen exposure. Raised 2026 organic-sales-growth guide to ~10%. | Cyclical industrial exposure; data-center order digestion; supply chain; integration risk | 77 |
▼ Downside skew — 1yrconviction
| Ticker | Thesis | Key risk | Score |
|---|---|---|---|
| TSLA | Extreme valuation on a decelerating auto business — Street models only ~1% delivery growth in 2026 after a Q1 miss (358,023 units); margin pressure from price cuts and Chinese/legacy EV share loss. Priced for AI/robotaxi optionality. | Robotaxi/FSD/Optimus milestones or any delivery beat can trigger violent squeezes; multiple is narrative-driven, not fundamental | -80 |
| INTC | Thesis has inverted to a valuation short — Intel rallied ~500% on foundry/AI/government-stake enthusiasm to a ~$140 high and trades at a nosebleed multiple against negative TTM EPS, while 18A/18A-P yields are unlikely to be profitable until late 2026-2027. Fell ~21% into Jul 8, 2026; BofA flagged 'bubble' risk. | A marquee external 18A foundry customer win re-rates it higher; HSBC $200 bull target; government/SoftBank backing provides squeeze fuel | -75 |
| HUM | Structurally impaired Medicare Advantage margins — FY26 adj EPS guide 'at least $9.00' came in ~$3 below consensus (~$11.92); low star ratings create a ~$3.5B 2026 profit headwind; near-flat proposed 2027 MA benchmark; lost the CMS star-ratings suit again. | Small-cap near lows with aggressive buybacks and crowded bearish sentiment; any better 2027 final rate or star-ratings recovery squeezes | -76 |
| NKE | Elliott Hill turnaround stalling — Greater China -~12%, Converse -~32%, Nike Direct -~7%; forward EPS reset sharply lower (~$1.51 vs $2.17), with a formal guidance cut expected before the November investor day. | Elevated short interest ~4.2-4.7%; heavy April-2026 insider buying near $42; early wholesale 'Win Now' wins; consensus still net Buy (avg PT ~$51) | -68 |
| DG | Guidance reset + management changes forced lower sales/margin/new-store-return assumptions; Redburn argues a structurally lower multiple is warranted on weaker unit economics; SG&A deleverage + WOTC tax-credit expiration drag. | Consensus still Buy (avg PT ~$131); Barclays Overweight; Q1 beat ($2.00 vs $1.89); trade-down tailwind; ~16x 'cheap' optics | -64 |
| RIVN | Cash-burn/dilution trap — Wolfe models ~$2.1B 2026 EBITDA loss (worse than consensus) and FCF burn toward ~$4B; Q1 2026 gross margin collapsed to 9% from 17% YoY; R2-ramp risk plus repeated equity raises. | Heavy AI/autonomy narrative optionality; VW JV backing; R2 launch hype can spark sharp squeezes | -70 |
| MRNA | Post-COVID revenue collapse (~72% over three years); FY26 revenue guided ~$2.09B with profitability distant; stock surged ~128-148% YTD, stretching valuation vs an unproven oncology/rare-disease pipeline. | Pipeline/regulatory wins can spark squeezes; large cash pile; low price-to-assets; RBC raised target to $45 (mixed) | -60 |
| LULU | First potential full-year revenue decline since IPO — weak Americas demand, China growth 'hit a wall', misfired launches, margin compression; soft FY26 guide (EPS $12.10-12.30 vs $13.26); no permanent CEO until Sept 2026. | Late-stage: valuation already reset to ~10-11x forward (~78% off peak); ~$1.6B buyback + ~$1.5B cash; possible sentiment inflection on new CEO; reported Michael Burry position UNVERIFIED | -62 |
| PFE | Twin structural drags in 2026 — ~$1.5B patent-cliff hit (Eliquis, Xtandi, Ibrance, Xeljanz LOEs) plus a further ~$1.5B COVID (Comirnaty/Paxlovid) decline; rising Seagen debt; unproven ability to bridge LOEs. Company FY26 EPS guide $2.80-3.00 sits below ~$3.05 consensus. | High dividend yield supports the stock and raises borrow cost; obesity-pipeline optionality; much is already priced in (widely bearish) | -58 |
| DXCM | Secular threat from GLP-1 adoption shrinking the insulin-treated diabetes TAM (core CGM market) plus rising CGM competition and pricing pressure; the Type-2 non-insulin/Stelo offset is commercially unproven. | Stock already -15.9% over trailing year; a Type-2/Stelo inflection or GLP-1 turning into a CGM tailwind squeezes; ~28x valuation 'not demanding' | -55 |
C · Options Heat
Where the premium is paying up
| Ticker | Signal | Read | Implication | Lag |
|---|---|---|---|---|
| SPX/EQUITY | pc_skew | CBOE equity put/call ~0.69 (Jul 7) vs ~1.33 (Jul 3) — irreconcilable free readings; total P/C ~0.99 (Jun 25, ~neutral) | Ambiguous: 0.69 = complacent/bullish, 1.33 = hedging/fearful. Treat as UNVERIFIED. | Free aggregator P/C values are contradictory and 1-2+ weeks stale; Cboe's own daily stats page is the tier-1 source and was not retrievable in detail. |
| MARKET | vol_oi | One session this week ~75M option contracts with calls dominating | bullish/complacent broad-tape skew | From a Barchart write-up (~Jun 20 referenced); stale, directional color only. |
| OXY | vol_oi | Volume ~258k, ~5.4x 30-day avg, 3-month high | bullish bets amid oil rally | Barchart write-up ~Jun 2026; lagged/partial free tier. |
| ASX | vol_oi | Vol ~6.6x 30-day avg; Jul 17 $47.50 call = 21% of volume | bullish/speculative on semis | Barchart ~Jun 20 write-up targeting Jul 17 expiry; verify live. |
| PEP | iv_spike | Jul 10 weekly call IV ~63 into Jul 9 pre-market Q2 earnings; Sep $155 call block (~4k) | hedging / elevated event premium (2-sided) | TipRanks free tier, 1-2 sessions stale. |
| INTC | iv_spike | 30-day IV ~99, top of 52-wk range (38-99) | very elevated expected move; 2-sided/uncertain | TipRanks IV report Jul 8; free-tier snapshot. |
| AVGOCHWYPYPLSTLAWMT | vol_oi | Flagged 'cheap lottery-ticket call' interest | bullish/speculative | Barchart write-up ~Jul 4; up to several sessions stale. |
D · Catalyst Calendar
Upcoming events
| Date | Event | Tickers | IV move |
|---|---|---|---|
| 2026-07-09 | PepsiCo Q2 earnings (pre-market); consensus EPS ~$2.19-2.21 | PEP | high |
| 2026-07-10 | Delta Air Lines Q2 earnings; EPS ~$1.43-1.44 exp (YoY decline) | DAL | normal |
| 2026-07-10 | Levi Strauss earnings; expected move ~±8.9% | LEVI | high |
| 2026-07-10 | Helen of Troy earnings; expected move ~±18.8% | HELE | high |
| 2026-07-14 | US CPI (June 2026), 8:30 ET | CPI | unknown |
| 2026-07-14 | JPMorgan Q2 earnings (pre-market) — big-bank kickoff | JPM | unknown |
| 2026-07-14 | Wells Fargo Q2 earnings (pre-market) | WFC | unknown |
| 2026-07-14 | Citigroup Q2 earnings (pre-market) | C | unknown |
| 2026-07-15 | US PPI (June 2026), 8:30 ET | PPI | unknown |
| 2026-07-15 | Bank of America Q2 earnings (date disputed Jul 14 vs Jul 15; UNVERIFIED) | BAC | unknown |
| 2026-07-16 | US Retail Sales (June 2026), 8:30 ET | RETAIL | unknown |
| 2026-07-16 | Weekly Initial Jobless Claims (standard Thu release; exact date UNVERIFIED) | CLAIMS | normal |
E · Trade Ideas
What the data implies
MPClong · track A
Rationale Refiner leverage to the Iran-conflict oil/diesel spike (+5.4%; ULSD futures +13% on Russia export ban) with group confirmation (VLO/PBF/DINO). This is a macro/oil-momentum trade, not a fundamental re-rating.
Invalidation A durable de-escalation headline + WTI back below its pre-spike ~$70 base; also a break of the breakout-day low.
Risk Whipsaw risk is high — the entire move can reverse on a single ceasefire headline. Oil-momentum, not thesis.
AZNshort · track A
Rationale Phase III CARDIO-TTRansform (Wainua) primary-endpoint miss is a fundamental late-stage failure that erased ~£19-27B; US ADR (-1.99%) materially lagged the -9% London move, suggesting the ADR had further to catch down.
Invalidation Management reframes the trial with a salvageable subgroup/secondary win, or a same-week offsetting pipeline positive; ADR reclaiming the pre-news level.
Risk Diversified large-cap pharma — one failed trial is not existential; the drop can be bought. Borrow/ADR arb frictions apply.
GEVlong · track B
Rationale Structural data-center electricity-demand thesis with hard fundamentals: orders +71% YoY, backlog +$13B to $163B, FY26 revenue guide raised — strong positive estimate-revision trend and durable multi-year catalysts (gas turbines, grid, SMR).
Invalidation A cut to backlog/order growth, a guide-down, or evidence of power-demand/data-center capex rolling over.
Risk Rich valuation after a large run; wind-segment losses and long-cycle execution can create drawdowns even if the thesis holds.
TSLAshort · track B
Rationale Valuation short: extreme multiple on a decelerating auto business (~1% 2026 delivery growth modeled after a Q1 miss), with three banks cutting PTs/EPS. Downside is a de-rating toward auto fundamentals.
Invalidation A credible robotaxi/FSD commercialization milestone, an Optimus order, or a clear delivery re-acceleration — any of which can trigger a violent squeeze.
Risk One of the most squeeze-prone large caps; the multiple is narrative-driven. Size small and cap risk with options.
PEPneutral · track A
Rationale Elevated event premium (weekly call IV ~63) into Jul 9 pre-market Q2 earnings with weak beverage scanner data (~-6% volumes) already pressuring the stock — a setup for an outsized 2-sided move rather than a clear directional edge.
Invalidation For any post-earnings directional lean: a close back through the pre-earnings range boundary in the opposite direction.
Risk IV crush post-report punishes long premium if the move is small; staples 'safety' bid can mute the reaction.
Methodology & limitations
- Free options data (P/C, unusual activity, IV) is LAGGED 1-3+ sessions and partial; no true block/sweep tape. All options claims carry a data-lag caveat.
- CBOE equity put/call returned contradictory free readings (0.69 vs 1.33) — labeled UNVERIFIED; no single clean figure.
- Many market caps and several intraday % moves are approximate/UNVERIFIED — aggregator figures for mega-caps (NVDA, GOOGL, INTC, ORCL) did not reconcile to price and are set null or labeled.
- Some Track A names (AA, BE, NCLH) sit near the $10B floor; BE and AA borderline/UNVERIFIED. Track A 'falling' returned 8 defensible ≥~$10B names, not 10, to avoid padding with reversed/sympathy moves (Wed's tech decliners rebounded Thu).
- ORCL's decline is a multi-week move surfaced in the 48h window, not a fresh 48h catalyst — flagged in its 'why'.
- Individual dated analyst actions were largely sourced via aggregators (Benzinga/MarketBeat/Public/TipRanks) rather than primary desk notes — confirm wording/date before use.
- DEEP_DIVE_WATCHLIST parameter was not supplied, so no in_deep_dive_library markers were applied.
- Index levels and VIX rely on search-surfaced article excerpts (JS-rendered pages returned empty on direct fetch); VIX exact print UNVERIFIED.
Not financial advice. Educational/analytical only — generated by Multi-desk equity research scanner (Cowork) — RUN_DATE 2026-07-09, recency window 48h, free/web-searchable data only. Do your own diligence.